AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 141 min read$CDXS

MOORE ALISON sold $9K of CDXS

MOORE ALISON (President and CEO) sold 6,335 shares of CODEXIS, INC. (CDXS) at $1.36 on 2026-10-12.

Original reporting
SEC EDGAR · MOORE ALISON
Published Oct 14, 2026, 9:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 9:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CDXS
Bearish
high confidence
Mentioned
$CDXS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CDXSBearishLow
01

Why it matters

A modest insider sell by the CEO may slightly depress the stock but is unlikely to drive significant price movement.

02

Market read

Provides a fresh, primary disclosure of an insider sale, useful for short‑term traders monitoring insider activity.

03

What to watch

The insider retains a large stake (244,171 shares) indicating continued confidence.

Relevance 3/10Novelty 3/10Timing: post-filing today

Background

Form 4 filings disclose insider transactions and are primary sources of corporate insider activity.

Company-level read

Ticker impact

$CDXSBearishHigh confidence
Context

President/CEO Alison Moore sold 6,335 shares of Codexis for $8,619.40 on 2026-10-12.

Expected impact

likely slight pressure as the market prices in the insider sell

Evidence & confidence

A small insider sale by the CEO signals potential lack of confidence, but the amount is trivial relative to total holdings.

Market effects

Sector

Minimal impact on the biotech/biopharma sector.

Regional

No significant regional effect.

Global

Limited to Codexis investors.

Counterpoint

What could challenge this read

The sale could be a routine liquidity move, not a negative signal.

Key entities

  • Company
    Codexis, Inc.

    Biotech firm listed on NASDAQ under CDXS.

  • Person
    Alison Moore

    President and CEO of Codexis.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CDXS insider trading history →

Related articles

AUG 19
$CDXSMedAI 8/10

Codexis (CDXS) Q2 2026 Earnings Call Transcript

Codexis (CDXS) reported Q2 2026 revenue of $14.9M, down from $15.3M in Q2 2025. Product revenue rose to $13.2M, while R&D revenue fell to $1.7M. Net loss narrowed to $12.0M. The company guided full-year revenue to $72M-$76M and maintained a high 60% gross margin target. It plans to invest $25M in a GMP facility and expects a 30-fold increase in siRNA market demand by 2035. CDXS has 14 commercial products and 15 clinical programs in Phase II/III. Management highlighted progress in ECOsynthesis pl

fool.com6 min
AUG 11
$CDXSMed

Codexis Reports Second Quarter 2026 Financial Results

CODEXIS, INC. (CDXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Codexis Reports Second Quarter 2026 Financial Results Reports revenue of $14.9 million for the second quarter of 2026, company reiterates full-year financial guidance Shared new advances in RNA therapeutic manufacturing at TIDES US showing that its ECO Synthesis ® Ma

SEC EDGAR 8-K6 min
JUL 23
$CDXSMed

CODEXIS, INC. (CDXS): Results of Operations and Financial Condition

CODEXIS, INC. (CDXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. 8-K false 0001200375 0001200375 2026-07-23 2026-07-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23,

SEC EDGAR 8-K2 min